March 11, 2019
BEDFORD, Mass.–(BUSINESS WIRE)–Anika Therapeutics, Inc. (NASDAQ: ANIK), a global, integrated orthopedics and regenerative medicines company specializing in therapeutics based on its proprietary hyaluronic acid (“HA”) technology, today announced plans to showcase its innovative commercial and pipeline portfolio at the upcoming American Academy of Orthopedic Surgeons (AAOS) Annual Meeting, March 12-16 in Las Vegas, Nevada. Anika will be exhibiting its injectable, HA-based, surgical bone repair therapy in addition to its viscosupplement (CINGAL) and cartilage repair (HYALOFAST) solutions.
“We’re excited to preview our bone repair therapy at the 2019 AAOS Annual Meeting, the largest gathering of orthopedic surgery professionals from around the world,” said Joseph Darling, President and CEO, Anika Therapeutics. “Our bone repair therapy, which we plan to launch in the U.S. using our hybrid commercial model in the second half of 2019, represents a major advance in the surgical treatment of bone defects and marks an important milestone in the progress of our regenerative medicine pipeline as it will be our first internally developed surgical therapy to launch in the U.S. We look forward to educating the orthopedic surgical community at AAOS on the application and clinical advantages of this innovative new treatment, as well as our broader orthopedic medicine portfolio.”
Below are highlights of Anika’s planned activities:
- AAOS Annual Meeting – Booth 2570 – March 13 – 15, 2019
Darling added, “Our participation in the 2019 AAOS Annual Meeting represents an important opportunity for Anika to continue building relationships with and gaining clinical insights from U.S. orthopedic medicine thought-leaders who will be critical to the success of our hybrid commercialization model and adoption of our newly introduced treatments.”
About Anika Therapeutics, Inc.
Anika Therapeutics, Inc. (NASDAQ: ANIK) is a global, integrated orthopedic and regenerative medicines company based in Bedford, Massachusetts. Anika is committed to improving the lives of patients with degenerative orthopedic diseases and traumatic conditions with clinically meaningful therapies along the continuum of care, from palliative pain management to regenerative tissue repair. The Company has over two decades of global expertise developing, manufacturing, and commercializing more than 20 products based on its proprietary hyaluronic acid (HA) technology. Anika’s orthopedic medicine portfolio includes ORTHOVISC®, MONOVISC®, and CINGAL®, which alleviate pain and restore joint function by replenishing depleted HA, and HYALOFAST, a solid HA-based scaffold to aid cartilage repair and regeneration. For more information about Anika, please visit www.anikatherapeutics.com.
Forward-Looking Statements
The statements made in the second sentence of the second paragraph of this press release, which are not statements of historical fact, are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These statements include, but are not limited to, those relating to the Company’s U.S. commercial efforts with respect to its bone repair therapy. These statements are based upon the current beliefs and expectations of the Company’s management and are subject to significant risks, uncertainties, and other factors. The Company’s actual results could differ materially from any anticipated future results, performance, or achievements described in the forward-looking statements as a result of a number of factors including, but not limited to, (i) the Company’s ability to successfully commence and/or complete clinical trials of its products on a timely basis or at all; (ii) the Company’s ability to obtain pre-clinical or clinical data to support domestic and international pre-market approval applications, 510(k) applications, or new drug applications, or to timely file and receive FDA or other regulatory approvals or clearances of its products; (iii) that such approvals will not be obtained in a timely manner or without the need for additional clinical trials, other testing or regulatory submissions, as applicable; (iv) the Company’s research and product development efforts and their relative success, including whether we have any meaningful sales of any new products resulting from such efforts; (v) the cost effectiveness and efficiency of the Company’s clinical studies, manufacturing operations, and production planning; (vi) the strength of the economies in which the Company operates or will be operating, as well as the political stability of any of those geographic areas; (vii) future determinations by the Company to allocate resources to products and in directions not presently contemplated; (viii) the Company’s ability to successfully commercialize its products, in the U.S. and abroad; (ix) quarterly sales volume variation experienced by the Company, which can make future results difficult to predict and period-to-period comparisons potentially less meaningful; (x) the Company’s ability to provide an adequate and timely supply of its products to its customers; and (xi) the Company’s ability to achieve its growth targets. Additional factors and risks are described in the Company’s periodic reports filed with the Securities and Exchange Commission, and they are available on the SEC’s website at www.sec.gov. Forward-looking statements are made based on information available to the Company on the date of this press release, and the Company assumes no obligation to update the information contained in this press release.
Contacts
For Investor Inquiries:
Anika Therapeutics, Inc.
Sylvia Cheung, 781-457-9000
Chief Financial Officer
For Media Inquiries:
W2O Group
Sonal Vasudev, 917-523-1418
sonal@w2ogroup.com
